Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) reported a third-quarter net loss of $13.9 million and updated its bladder cancer development program. Loss per share was $0.12, versus $0.30 a year earlier, while total net loss widened from $10.1 million. Cash, equivalents and short-term investments totaled $202.1 million at September 30, 2026; the company expects funding through 2029.
In NDV-01’s Phase 2 bladder cancer study, 86% (12/14) of evaluable 12-month complete responders reaching 18 months remained in complete response. Two patients progressed to muscle-invasive disease at month 15; no Grade ≥3 treatment-related adverse events occurred. Relmada targets year-end 2026 investigational new drug application submissions for NDV-01 and sepranolone. NDV-01’s Phase 3 program, renamed SPECTRUM, and sepranolone’s Phase 2b Prader-Willi syndrome trial are planned to begin upon clearance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCash, equivalents and short-term investments reached $202.1 million, versus approximately $93.0 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Relmada expects funding through 2029, including completion of both NDV-01 Phase 3 registrational cohorts.
- Moderate point. Forward-looking: it has not happened yet and may not happen.NDV-01 application submission remains targeted for year-end 2026; a manufacturing supply plan is established through Phase 3 completion.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Sepranolone application submission remains targeted for year-end 2026, with Phase 2b planned after clearance.
- Moderate pointWritten FDA feedback confirmed alignment on two NDV-01 registrational pathways, including designs, populations and primary endpoints.
- Moderate pointThird-quarter general and administrative expense fell to $3.9 million from $6.3 million a year earlier.
8 minor points
- Minor pointNDV-01 maintained complete response in 86% (12/14) of evaluable 12-month responders reaching 18 months.
- Minor pointBCG-unresponsive subgroup maintained complete response in 88% (7/8) of evaluable 12-month responders reaching 18 months.
- Minor pointNDV-01 overall complete response rates were 94% (48/51) anytime and 77% (24/31) at 12 months.
- Minor pointBCG-unresponsive complete response rates were 96% (22/23) anytime and 73% (11/15) at 12 months.
- Minor pointProgression-free and bladder-removal-free survival were both 100% through 12 months.
- Minor pointNDV-01 safety showed no Grade ≥3 treatment-related adverse events, treatment-related serious adverse events or treatment-related discontinuations.
- Minor pointThird-quarter net investment income increased to $2,274,541 from $247,013 a year earlier.
- Minor pointNine-month net investment income increased to $5,535,697 from $1,008,758 a year earlier.
Negative
- Moderate pointThird-quarter net loss widened to $13.9 million from $10.1 million; loss per share fell to $0.12 from $0.30.
- Moderate pointThird-quarter research and development expense rose to $9.2 million from $4.0 million a year earlier.
- Moderate pointThird-quarter operating cash use increased to $12.6 million from $6.7 million a year earlier.
- Moderate pointNine-month net loss widened to $45.8 million from $37.5 million; loss per share fell to $0.44 from $1.16.
- Moderate pointNine-month research and development expense rose to $25.7 million from $18.8 million a year earlier.
- Moderate pointNine-month operating cash use increased to $37.3 million from $31.2 million a year earlier.
- Moderate pointCommon shares outstanding increased to 106,694,846 at September 30, 2026, from 73,333,622 at December 31, 2025.
8 minor points
- Minor pointTwo BCG-naïve patients progressed from T1 disease at entry to muscle-invasive T2a disease at month 15.
- Minor pointNDV-01 Phase 3 initiation remains dependent on investigational new drug application clearance.
- Minor pointSepranolone Phase 2b initiation depends on application clearance; pre-filled syringe stability testing is being finalized.
- Minor pointNine-month general and administrative expense rose to $21.9 million from $20.0 million a year earlier.
- Minor pointThird-quarter realized investment losses widened to $435,122 from $81,438 a year earlier.
- Minor pointThird-quarter unrealized investment losses were $2,605,184, versus a $70,275 gain a year earlier.
- Minor pointNine-month realized investment losses were $482,284, versus a $28,717 gain a year earlier.
- Minor pointNine-month unrealized investment losses were $3,312,539, versus a $212,210 gain a year earlier.
News Explained
During the first nine months of 2026, Relmada Therapeutics issued 29,474,569 common shares for net proceeds of
Key Figures
- 18-month complete response
- 86% (12/14)
- Evaluable patients who remained in complete response at 18 months
- BCG-unresponsive 18-month complete response
- 88% (7/8)
- Evaluable patients who remained in complete response at 18 months
- Progression to muscle-invasive disease
- 2 patients
- BCG-naïve patients at the Month 15 assessment
- Anytime complete response rate
- 94% (48/51)
- Updated 12-month efficacy results; evaluable patients
- 12-month complete response rate
- 77% (24/31)
- Updated 12-month efficacy results; evaluable patients
- Grade ≥3 treatment-related adverse events
- 0 reported
- Safety and tolerability update
- Cash, cash equivalents and short-term investments
- $202.1 million
- As of September 30, 2026; expected to fund operations through 2029
- Net loss
- $13.9 million ($0.12 per share)
- Third quarter ended September 30, 2026
Previous Earnings Reports
-
Cash of $217.7 million supported runway through 2029 as the company advanced NDV-01 and sepranolone.
-
NDV-01 12-month complete-response rates were 76% overall and 80% in BCG-unresponsive patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cmc technical
nmibc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance
- Long-term extension NDV-01 Phase 2 data demonstrate continued durability of response:
86% of 12-month complete responders remained in complete response at 18 months, with no Grade ≥3 treatment-related adverse events or discontinuations - Registrational Phase 3 program renamed SPECTRUM; two independent registrational pathways in NMIBC remain unchanged
- Cash, cash equivalents and short-term investments of approximately
$202.1 million as of September 30, 2026, expected to fund operations through 2029
CORAL GABLES, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including 18-month results from the NDV-01 Phase 2 study, the registrational Phase 3 SPECTRUM program, and continued progress toward the planned year-end 2026 Investigational New Drug (IND) submission for NDV-01 and sepranolone.
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program,” said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.
“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability,” added Bipin Dalmia, Chief Business Officer of Relmada Therapeutics. “Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”
CMC and Manufacturing Update
NDV-01: NDV-01 CMC program is on track for IND submission by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through completion of the Phase 3 SPECTRUM program.
Sepranolone: The Company is finalizing the stability testing of the pre-filled syringe (PFS) delivery system to enable sepranolone IND submission, which is on track for year-end 2026. We expect to start the Phase 2b trial in Prader-Willi Syndrome upon IND clearance.
NDV-01 Clinical Update
Phase 2 Study: Initial 18-month results from the ongoing Phase 2 TRGC-011 study of NDV-01 in high-risk NMIBC continue to support extended durability of NDV-01 complete responses and continued favorable tolerability profile.
- Initial 18-month durability results: 23 patients in complete response (CR) at 12 months continued into the long-term extension (LTE).
86% (12/14) of evaluable patients who reached 18 months remained in CR. In the BCG-unresponsive subgroup, 11 patients continued into the LTE, and88% (7/8) of evaluable patients who reached 18 months remained in CR. Two BCG-naïve patients (T1 at study entry) progressed to muscle-invasive disease (T2a) at the Month 15 assessment. - Updated 12-month efficacy results: Among 51 evaluable patients, the anytime CR rate was
94% (48/51) and the 12-month CR rate was77% (24/31). In the BCG-unresponsive subgroup, the anytime CR rate was96% (22/23) and 12-month CR rate was73% (11/15). Through 12-months, both progression-free and cystectomy-free survival was100% . - Safety and tolerability: To date, there were no Grade ≥3 treatment-related adverse events (TRAEs), no treatment-related serious adverse events, and no treatment-related discontinuations.
Phase 3 SPECTRUM Program: The NDV-01 Phase 3 program remains unchanged and is designed to pursue two independent registrational pathways in NMIBC:
- A single-arm study in second-line (2L) high-risk BCG-unresponsive carcinoma in situ (CIS) ± Ta/T1 (Cohort 2UC), together with a separate single-arm 2L high-risk BCG-unresponsive Ta/T1 w/o CIS exploratory cohort (Cohort 2UP).
- A randomized study evaluating NDV-01 as adjuvant therapy following transurethral resection of bladder tumor (TURBT) versus observation in low-grade intermediate-risk NMIBC (Cohort IRA).
The Company has changed the name of its Phase 3 program from RESCUE to SPECTRUM to better reflect the potential breadth of NDV-01 across the entire NMIBC disease spectrum. Clinical trial sites are engaged and preparing to initiate patient enrollment upon IND clearance.
Anticipated Upcoming Milestones
NDV-01:
- NDV-01 United States IND submission – By year-end 2026
- NDV-01 Phase 3 SPECTRUM program initiation – Upon IND clearance
Sepranolone:
- Sepranolone United States IND submission – By year-end 2026
- Sepranolone Phase 2b initiation in Prader-Willi Syndrome – Upon IND clearance
Financial Results
Third Quarter 2026 Financial Results
- Research and development expense for the three months ended September 30, 2026, totaled
$9.2 million , compared to$4.0 million for the three months ended September 30, 2025, an increase of$5.2 million . The increase was primarily attributable to higher NDV-01 and sepranolone study preparation costs, increased manufacturing and drug storage costs and higher employee compensation, partially offset by lower stock-based compensation. - General and administrative expense for the three months ended September 30, 2026, totaled
$3.9 million compared to$6.3 million for the three months ended September 30, 2025, a decrease of approximately$2.4 million . The decrease was primarily driven by lower stock-based compensation and lower stock appreciation rights expense, partially offset by higher employee compensation and consulting services. - Net cash used in operating activities for the three months ended September 30, 2026, totaled
$12.6 million compared to$6.7 million for the three months ended September 30, 2025. - The net loss for the three months ended September 30, 2026, was
$13.9 million , or$0.12 per basic and diluted share, compared with a net loss of$10.1 million , or$0.30 per basic and diluted share, for the three months ended September 30, 2025. - As of September 30, 2026, the Company’s cash, cash equivalents, and short-term investments totaled
$202.1 million , compared to cash, cash equivalents, and short-term investments of approximately$93.0 million at December 31, 2025. - The Company’s current cash, cash equivalents, and short-term investments as of September 30, 2026, are expected to provide sufficient resources to fund Company operations through 2029, including completion of the two registrational cohorts of the NDV-01 Phase 3 SPECTRUM program.
- The Company had 106,694,846 shares outstanding, as of November 10, 2026.
Nine Months Ended September 30, 2026 Financial Results
- Research and development expense for the nine months ended September 30, 2026, totaled
$25.7 million , compared to$18.8 million for the nine months ended September 30, 2025, an increase of$6.9 million . The increase was primarily attributable to increased manufacturing and drug storage costs, higher employee compensation and higher stock appreciation rights expense, partially offset by lower study costs and lower stock-based compensation. - General and administrative expense for the nine months ended September 30, 2026, totaled
$21.9 million compared to$20.0 million for the nine months ended September 30, 2025, an increase of approximately$1.9 million . The increase was primarily driven by higher employee compensation, stock appreciation rights expense and consulting services, partially offset by lower stock-based compensation. - Net cash used in operating activities for the nine months ended September 30, 2026, totaled
$37.3 million compared to$31.2 million for the nine months ended September 30, 2025. - The net loss for the nine months ended September 30, 2026, was
$45.8 million , or$0.44 per basic and diluted share, compared with a net loss of$37.5 million , or$1.16 per basic and diluted share, for the nine months ended September 30, 2025.
Conference Call and Webcast Information
Relmada will host a conference call and webcast today at 4:30 PM ET to discuss recent business progress and financial results.
Date: Thursday, November 12, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.
About NDV-01
NDV-01 is a novel, sustained-release, intravesical co-formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The formulation is engineered to provide prolonged bladder retention and sustained drug release for up to 10 days. By forming a soft intravesical matrix, NDV-01 is designed to increase local drug exposure while limiting systemic toxicity. The treatment can be administered conveniently in an office setting in under 5 minutes without the need for anesthesia or specialized equipment. NDV-01 is encompassed by multiple patent applications that if issued, could provide protection until 2047.
About the NDV-01 Phase 3 SPECTRUM Registrational Pathways:
Relmada has received written FDA feedback confirming alignment on two registrational pathways for NDV-01, including study design, patient populations, and primary endpoints. The Company expects to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM program upon IND clearance.
About NMIBC
NMIBC represents 75
About Sepranolone and GABA Modulation
Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABAA receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome (PWS), Tourette syndrome, and obsessive-compulsive disorder (OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with a favorable safety profile. The Company is on track to submit the sepranolone IND by year-end 2026 and expects to initiate the Phase 2 study in Prader-Willi syndrome upon IND clearance.
About Prader-Willi Syndrome (PWS)
PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Forward-Looking Statements:
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, potential changes to the design, size or timing of the Phase 3 SPECTRUM studies, including as a result of updated treatment guidelines or third-party clinical data, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to successfully execute manufacturing and CMC activities for NDV-01 and/or sepranolone, including GMP manufacture of clinical trial material, manufacturing scale-up, process validation, timing of completion of manufacturing activities, and regulatory acceptance of manufacturing-related submissions, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive advantages, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
| Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets | ||||||||
| As of | ||||||||
| September 30, | As of | |||||||
| 2026 (Unaudited) | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,720,325 | $ | 3,496,540 | ||||
| Short-term investments | 196,402,988 | 89,509,710 | ||||||
| Other receivable | 10,912 | — | ||||||
| Prepaid expenses | 2,915,011 | 977,721 | ||||||
| Total current assets | 205,049,236 | 93,983,971 | ||||||
| Other assets | 247,379 | 19,500 | ||||||
| Total assets | $ | 205,296,615 | $ | 94,003,471 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,538,585 | $ | 1,568,944 | ||||
| Accrued expenses | 5,237,116 | 4,861,583 | ||||||
| Total current liabilities | 7,775,701 | 6,430,527 | ||||||
| Stock appreciation rights | 3,783,853 | 1,060,931 | ||||||
| Total liabilities | 11,559,554 | 7,491,458 | ||||||
| Commitments and Contingencies (See Note 8) | ||||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Class A convertible preferred stock, | — | — | ||||||
| Common stock, | 106,695 | 73,333 | ||||||
| Additional paid-in capital | 937,725,893 | 784,705,878 | ||||||
| Accumulated deficit | (744,095,527 | ) | (698,267,198 | ) | ||||
| Total stockholders’ equity | 193,737,061 | 86,512,013 | ||||||
| Total liabilities and stockholders’ equity | $ | 205,296,615 | $ | 94,003,471 | ||||
| Relmada Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||||||||||
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 9,217,440 | $ | 4,036,267 | $ | 25,699,073 | $ | 18,806,667 | ||||||||
| General and administrative | 3,878,983 | 6,291,079 | 21,870,130 | 19,960,421 | ||||||||||||
| Total operating expenses | 13,096,423 | 10,327,346 | 47,569,203 | 38,767,088 | ||||||||||||
| Loss from operations | (13,096,423 | ) | (10,327,346 | ) | (47,569,203 | ) | (38,767,088 | ) | ||||||||
| Other (expenses) income: | ||||||||||||||||
| Interest/investment income, net | 2,274,541 | 247,013 | 5,535,697 | 1,008,758 | ||||||||||||
| Realized (loss) gain on short-term investments | (435,122 | ) | (81,438 | ) | (482,284 | ) | 28,717 | |||||||||
| Unrealized (loss) gain on short-term investments | (2,605,184 | ) | 70,275 | (3,312,539 | ) | 212,210 | ||||||||||
| Total other (expense) income – net | (765,765 | ) | 235,850 | 1,740,874 | 1,249,685 | |||||||||||
| Net loss | $ | (13,862,188 | ) | $ | (10,091,496 | ) | $ | (45,828,329 | ) | $ | (37,517,403 | ) | ||||
| Loss per common share – basic and diluted | $ | (0.12 | ) | $ | (0.30 | ) | $ | (0.44 | ) | $ | (1.16 | ) | ||||
| Weighted average number of common shares outstanding – basic and diluted | 112,437,710 | 33,191,622 | 103,745,599 | 32,274,238 | ||||||||||||
| Relmada Therapeutics, Inc. Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) | ||||||||||||||||||||
| Three and Nine months ended September 30, 2026 | ||||||||||||||||||||
| Common Stock | Additional Paid-in | Accumulated | ||||||||||||||||||
| Shares | Par Value | Capital | Deficit | Total | ||||||||||||||||
| Balance – December 31, 2025 | 73,333,622 | $ | 73,333 | $ | 784,705,878 | $ | (698,267,198 | ) | $ | 86,512,013 | ||||||||||
| Stock based compensation | — | — | 956,186 | — | 956,186 | |||||||||||||||
| Proceeds from issuance of common stock, net | 29,474,569 | 29,475 | 150,352,510 | — | 150,381,985 | |||||||||||||||
| ATM Fees | — | — | (65,651 | ) | — | (65,651 | ) | |||||||||||||
| Cashless exercise of pre-funded warrants for common stock | 2,082,032 | 2,082 | (2,082 | ) | — | — | ||||||||||||||
| Net loss | — | — | — | (19,051,956 | ) | (19,051,956 | ) | |||||||||||||
| Balance – March 31, 2026 | 104,890,223 | 104,890 | 935,946,841 | (717,319,154 | ) | 218,732,577 | ||||||||||||||
| Stock based compensation | — | — | 902,903 | — | 902,903 | |||||||||||||||
| ATM fees | — | — | (66,273 | ) | — | (66,273 | ) | |||||||||||||
| Stock issuance costs | — | — | (199,879 | ) | — | (199,879 | ) | |||||||||||||
| Exercise of pre-funded warrants for common stock | 1,682,500 | 1,683 | — | — | 1,683 | |||||||||||||||
| Options exercised | 97,123 | 97 | 101,400 | — | 101,497 | |||||||||||||||
| Net loss | — | — | — | (12,914,185 | ) | (12,914,185 | ) | |||||||||||||
| Balance – June 30, 2026 | 106,669,846 | 106,670 | 936,684,992 | (730,233,339 | ) | 206,558,323 | ||||||||||||||
| Stock based compensation | — | — | 1,023,176 | — | 1,023,176 | |||||||||||||||
| Options exercised | 25,000 | 25 | 17,725 | — | 17,750 | |||||||||||||||
| Net loss | — | — | — | (13,862,188 | ) | (13,862,188 | ) | |||||||||||||
| Balance – September 30, 2026 | 106,694,846 | $ | 106,695 | $ | 937,725,893 | $ | (744,095,527 | ) | $ | 193,737,061 | ||||||||||
| Three and Nine months ended September 30, 2025 | ||||||||||||||||||||
| Common Stock | Additional Paid-in | Accumulated | ||||||||||||||||||
| Shares | Par Value | Capital | Deficit | Total | ||||||||||||||||
| Balance – December 31, 2024 | 30,174,202 | $ | 30,174 | $ | 676,373,822 | $ | (640,882,035 | ) | $ | 35,521,961 | ||||||||||
| Stock-based compensation | — | — | 3,572,769 | — | 3,572,769 | |||||||||||||||
| Issuance of Restricted Common Stock | 3,017,420 | 3,017 | 902,209 | — | 905,226 | |||||||||||||||
| Net loss | — | — | — | (17,559,465 | ) | (17,559,465 | ) | |||||||||||||
| Balance – March 31, 2025 | 33,191,622 | 33,191 | 680,848,800 | (658,441,500 | ) | 22,440,491 | ||||||||||||||
| Stock-based compensation | — | — | 3,448,453 | — | 3,448,453 | |||||||||||||||
| ATM Expenses | — | — | (73,021 | ) | — | (73,021 | ) | |||||||||||||
| Net loss | — | — | — | (9,866,442 | ) | (9,866,442 | ) | |||||||||||||
| Balance – June 30, 2025 | 33,191,622 | 33,191 | 684,224,232 | (668,307,942 | ) | 15,949,481 | ||||||||||||||
| Stock-based compensation | — | — | 3,607,554 | — | 3,607,554 | |||||||||||||||
| Net loss | — | — | — | (10,091,496 | ) | (10,091,496 | ) | |||||||||||||
| Balance – September 30, 2025 | 33,191,622 | $ | 33,191 | $ | 687,831,786 | $ | (678,399,438 | ) | $ | 9,465,539 | ||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Relmada Therapeutics’ third-quarter 2026 financial results?
Relmada reported a $13.9 million net loss, or $0.12 per basic and diluted share, for the quarter ended September 30, 2026. The year-earlier net loss was $10.1 million, or $0.30 per basic and diluted share.
What did Relmada’s NDV-01 Phase 2 study show at 18 months?
Among evaluable patients who had a complete response at 12 months and reached 18 months, 86% (12/14) remained in complete response. In the BCG-unresponsive subgroup, the corresponding result was 88% (7/8). Two BCG-naïve patients progressed to muscle-invasive disease at the month 15 assessment.
How are Relmada’s NDV-01 SPECTRUM Phase 3 studies designed?
SPECTRUM includes two independent registrational pathways in non-muscle invasive bladder cancer. One is a single-arm study in second-line, high-risk BCG-unresponsive carcinoma in situ, with or without Ta/T1 disease, alongside a separate exploratory cohort without carcinoma in situ. The other is a randomized study comparing NDV-01 with observation after tumor resection in low-grade, intermediate-risk disease.